MediWound Ltd. (MDWD)

NGM – Real vaqt narxi. Valyuta: USD

16.13

-0.33 (-2.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

MediWound to Report First Quarter 2026 Financial Results

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.

13.04.2026

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing Panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx ® in chronic wound care YAVNE, Israel, April 13, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today highlighted the publication of a peer-reviewed supplement in WOUNDS titled “Toward a Practical Framework for Debridement in Chronic Wounds: Findings From a United States-Based Multidisciplinary Consensus Panel.

07.04.2026

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel, April 7, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced multiple oral and poster presentations at three leading wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2026, taking place April 8–12 in Charlotte, North Carolina, and the European Wound Management Association (EWMA) 2026, taking place May 6–8 in Bremen, Germany.

02.04.2026

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

05.03.2026

MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript

05.03.2026

MediWound Files Annual Report on Form 20-F

MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026.

05.03.2026

MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates

MediWound (MDWD) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.36 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

13.04.2026

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

02.04.2026

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

05.03.2026

MediWound Files Annual Report on Form 20-F

05.03.2026

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational ; regulatory approvals expected in 2026 $17 million revenue in 2025 ; $54 million in cash at year-end; 2026–2028 revenue guidance reaffirmed Conference Call Today, March 5 , 202 6 , a t 8:30 a . m . Eastern Time YAVNE, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd.

MediWound Ltd. (MDWD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

MediWound Ltd. (MDWD)

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript

MediWound Files Annual Report on Form 20-F

MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript

MediWound Files Annual Report on Form 20-F

MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

Search stocks

MediWound Ltd. (MDWD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

MediWound Ltd. (MDWD)

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript

MediWound Files Annual Report on Form 20-F

MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript

MediWound Files Annual Report on Form 20-F

MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results